Neoplasms

All Conditions

Symptoms and General Pathology

Digestive System Diseases

Gland and Hormone Related Diseases

Rare Diseases

Adenocarcinoma

Neoplasm Metastasis

Pancreatic Neoplasms

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

Micronutrients

All Drugs and Chemicals

Antineoplastic Agents

Gastrointestinal Agents

Vitamins

Ascorbic Acid

Gemcitabine

Paclitaxel

Albumin-Bound Paclitaxel

Cisplatin

Pancrelipase

Pancreatin

Tubulin Modulators

Antimitotic Agents

Trace Elements

Antimetabolites

Antioxidants

Protective Agents

Vitamin C

ascorbic acid paclitaxel protein-bound cisplatin gemcitabine

125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days

Paclitaxel protein-bound

25mg/m2 in 500\*mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days

1000mg/m2 in 500\*mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days

Hitendra Patel, MD

The purpose of this study is to see if a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer.

Vitamin C is a nutrient found in food and dietary supplements. It protects cells and also plays a key role in making collagen (which provides strength and structure to skin, bones, tissues and tendons). High-dose vitamin C may be given by intravenous (IV) infusion (through a vein into the bloodstream) or orally (taken by mouth). When taken by intravenous infusion, vitamin C can reach much higher levels in the blood than when the same amount is taken by mouth. Some human studies of high-dose IV vitamin C in patients with cancer have shown improved quality of life, as well as improvements in physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss. Intravenous high-dose ascorbic acid has caused very few side effects in clinical trials.

Pancreatic cancer continues to be a very lethal disease. It was estimated that in 2016, 53,070 Americans would be diagnosed with pancreatic ductal adenocarcinoma (PDA), and 41,780 would die from the disease. This makes pancreatic cancer the third leading cause of death from cancer in the US.

PDA is the twelfth most common cancer in the world with 338,000 new cases diagnosed in 2012. It is estimated that worldwide there will be \> 300,000 deaths from pancreatic cancer. Furthermore unfortunately PDA is projected to be the second leading cause of death from cancer in the US by 2030.

Detection of pancreatic cancer has notoriously been very late in the disease and therefore the 5-year survival rate is only 8%, which is actually a slight improvement over the last few years. Right now the only potential cure for pancreatic cancer is surgical resection (if the disease is caught early). However only about 20% of PDA patients are eligible for potentially curable resection and unfortunately most (\> 80%) have recurrence of their cancer within 2 years of resection, and those recurrences are almost universally fatal.

Recently it has been shown that there are regimens that actually improve survival for patients with advanced stage IV PDA. Conroy and colleagues have developed the Folfirinox regimen, which in a large randomized trial improved survival over gemcitabine as a single agent. Von Hoff and colleagues developed the nanoparticle albumin (nab) associated paclitaxel plus gemcitabine regimen which improved survival over single agent gemcitabine. Even more recently Jameson and colleagues have presented a combined regimen of nab-paclitaxel + gemcitabine + cisplatin in a small 24 patient phase Ib/II trial which showed a response rate of 71% with 2 patients having complete response, a 1-year survival of 65% and a median survival of 16+ months.

While there have been multiple investigators and investigations into the use of ascorbic acid for patients with cancer (see ClinTrials.gov), its use has generally not been found to be of help for patients particularly when given orally - e.g. 10 grams daily.

Ascorbic Acid Paclitaxel Protein Bound Cisplatin Gemcitabine

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer

To determine the maximum tolerated dose (MTD) of high dose ascorbic acid (AA) with triple therapy of nanoparticle paclitaxel protein bound + cisplatin + gemcitabine (NABPLAGEM) in patients with advanced stage IV metastatic pancreatic cancer

Lab testing will be completed to evaluate normalization of CA19-19

Telephone follow up will be conducted every 12 weeks from the last dose of treatment to determine status of disease progression

Telephone follow up will be conducted every 12 weeks from the last dose of treatment to determine survival status

Changes in patient's self-reported quality of life will be determined by administering the MD Anderson Symptom Inventory (MDASI-GI)

Cancer Research UK

Stand Up To Cancer

Lustgarten Foundation

Destroy Pancreatic Cancer

Translational Genomics Research Institute

HonorHealth Research Institute

Hitendra Patel

Associate Professor

25mg/m2 in 500 mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days

1000mg/m2 in 500 mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days

Ben George, MD

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Changes in patient's self-reported pain levels will be determined by administering the Brief Pain Inventory (BPI).

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer	NCT03697239	Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta...	Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine	18 Years -	University of California, San Diego
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer	NCT03697239	Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta...	Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine	18 Years -	University of California, San Diego
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer	NCT03908333	Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta...	Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine	18 Years -	Medical College of Wisconsin
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer	NCT03908333	Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta...	Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine	18 Years -	Medical College of Wisconsin
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer	NCT03697239	Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta...	Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine	18 Years -	University of California, San Diego

Spots Global Cancer Trial Database for nanoparticle paclitaxel protein bound